0 2.66930037636893E-05 -0.000987641139257413 -0.000160158022582287 -0.0011477991618397 -0.00226890531991556 -0.00274937938766242 -0.000373702052691953
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]

Biogen Inc. (BIIB)  More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferies say could help sustain the company's long-standing position in the rare disease market. According to the analysts, the decision was largely anticipated by investors despite earlier regulatory delays tied to manufacturing issues described as “benign.” The newly approved regimen, often referred to as high-dose Spinraza, is expected to reinforce the durability of Biogen's SMA franchise, which generates more than $1.5 billion annually. Spinraza, also known as nusinersen, has been a cornerstone SMA therapy for years. The updated dosing approach includes larger loading doses followed by higher maintenance levels, which analysts say may address the “waning-off effect experienced by patients” and improve the overall durability of response. This could also expand uptake among adult patie [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]

Biogen Inc.  (BIIB) 
More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferies say could help sustain the company's long-standing position in the rare disease market. According to the analysts, the decision was largely anticipated by investors despite earlier regulatory delays tied to manufacturing issues described as “benign.” The newly approved regimen, often referred to as high-dose Spinraza, is expected to reinforce the durability of Biogen's SMA franchise, which generates more than $1.5 billion annually. Spinraza, also known as nusinersen, has been a cornerstone SMA therapy for years. The updated dosing approach includes larger loading doses followed by higher maintenance levels, which analysts say may address the “waning-off effect experienced by patients” and improve the overall durability of response. This could also expand uptake among adult patie [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS